I’m Robb Fahrion, Partner of Migration.
I’m not a financial advisor, just a guy with a thing for marketing, money, and making systems tick. Biotech caught my interest not only for the science but for the structure behind it. There’s a lot happening beneath the surface—and the more I dig in, the more I see where the real opportunity might be.
The Curiosity That Sparked This Article
No pitch—just a company that caught my eye for the right reasons. Tharimmune (NASDAQ: THAR) wasn’t making noise, but it was making moves. And in biotech, that distinction matters. Quiet focus tends to mean the team’s too busy building to chase headlines.
What started as a quick read turned into a longer dive. The more I found, the more I wanted to know. Licensing a late-stage asset like TH104 and targeting rare diseases isn’t a shot in the dark. It’s a calculated approach that aligns risk with real, unmet need. That’s the kind of bet I pay attention to—not hype, but discipline.
